Aratana Therapeutics PT Raised to $38.00 at JMP Securities (PETX)
Research analysts at JMP Securities raised their target price on shares of Aratana Therapeutics (NASDAQ:PETX) from $16.00 to $38.00 in a report released on Thursday, AmericanBankingNews.com reports. JMP Securities’ price target would indicate a potential upside of 54.60% from the company’s current price.
Aratana Therapeutics (NASDAQ:PETX) traded down 0.57% on Thursday, hitting $24.58. The stock had a trading volume of 107,395 shares. Aratana Therapeutics has a 1-year low of $6.56 and a 1-year high of $15.12. The stock’s 50-day moving average is $9.38 and its 200-day moving average is $9.25. The company’s market cap is $538.2 million.
Aratana Therapeutics (NASDAQ:PETX) last announced its earnings results on Monday, August 12th. The company reported ($4.62) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($10.21) by $5.59. Analysts expect that Aratana Therapeutics will post $-4.41 EPS for the current fiscal year.
Separately, analysts at Lazard Capital Markets raised their price target on shares of Aratana Therapeutics from $28.00 to $39.00 in a research note to investors on Tuesday, October 15th. They now have a “buy” rating on the stock. Four investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $36.67.
Aratana Therapeutics, Inc is a development-stage biopharmaceutical company. As of March 20, 2013, the Company has three licensed compounds in development for six product approvals in cats and dogs in each of the United States and Europe.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.